Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
World Health Organization, International Society of Hypertension.
1999 WHO-ISH Guidelines for the management of hypertension.
J Hypertens, 17 (1999), pp. 151-183
[2.]
Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Arch Intern Med, 157 (1997), pp. 2413-2446
[3.]
J.R. Banegas, F. Rodríguez-Artalejo, J.J. de la Cruz, B. de Andrés, J. Rey.
Mortalidad relacionada con la hipertensión y la presión arterial en España.
Med Clin (Barc), 112 (1999), pp. 489-494
[4.]
J. Stokes, W.B. Kannel, P.A. Wolf, R.B. D'Agostino, L.A. Cupples.
Blood pressure as a major risk factor for cardiovascular disease: the Framingham Study. 30 years of follow-up.
Hypertension, 13 (1989), pp. I-13-I-18
[5.]
Multiple Risk Factor Intervention Trial Research Group.
Multiple Risk Intervention Trial (MRFIT).
JAMA, 248 (1982), pp. 1465-1472
[6.]
J. Stamler, R. Stamler, J.D. Neatin.
Blood pressure, systolic and diastolic, and cardiovascular risk.
Arch Intern Med, 153 (1993), pp. 598-615
[7.]
Veterans Administration Cooperative Study Group on Antihypertensive Agents.
Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg.
JAMA, 202 (1967), pp. 1028-1034
[8.]
Veterans Administration Cooperative Study Group on Antihypertensive Agents.
Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg.
JAMA, 213 (1970), pp. 1143-1152
[9.]
Hypertension Detection and Follow-up Program Cooperative Group.
Five year finding of the Hypertension Detection and Follow-up Program I: Reduction in mortality of persons with high blood pressure, including mild hypertension.
JAMA, 242 (1979), pp. 2562-2571
[10.]
Report by the Management Committee.
The Australian therapeutic trial in mild hypertension.
Lancet, 1 (1980), pp. 1261-1267
[11.]
A. Helgeland.
Treatment of mild hypertension: a five year controlleddrug trial. The Oslo Study.
Am J Med, 69 (1980), pp. 725-732
[12.]
Medical Research Council Working Party.
MRC trial of treatment of mild hypertension. Principal results.
BMJ, 291 (1985), pp. 97-104
[13.]
S. McMahon, R. Peto, J. Cutler, R. Collins, P. Sorlie, J. Neaton, et al.
Blood pressure, stroke and coronary heart disease. Part 1. Prolonged difference in blood pressure prospective observational studies corrected for the regression dilution bias.
Lancet, 335 (1990), pp. 765-774
[14.]
R. Collins, R. Peto, S. MacMahon, P. Herbert, N. Fiebach, K.A. Eberlein, et al.
Blood pressure, stroke, and coronary heart disease. Part 2, shortterm reductions in blood pressure: overview of randomised drug trials in their epidemiological context.
Lancet, 335 (1990), pp. 827-838
[15.]
R. Collins, S. McMahon.
Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary heart disease.
Bri Med Bull, 50 (1994), pp. 272-298
[16.]
A. Amery, P. Brixko, D. Clement, A. de Schaepdryver, R. Fagard, J. Forte, et al.
Mortality and Morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial.
Lancet, 1 (1985), pp. 1349-1354
[17.]
SHEP Cooperative Research Group.
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP).
JAMA, 265 (1991), pp. 3255-3264
[18.]
B. Dahlöf, L.H. Lindholm, L. Hansson, B. Schersten, T. Ekbom, P.O. Wester.
Morbidity and mortality in the Old Patients with Hypertension (STOP-Hypertension).
Lancet, 338 (1991), pp. 1281-1285
[19.]
MRC Working Party.
Medical Research Council trial of treatment of hypertension in older adults: principal results.
BMJ, 304 (1992), pp. 405-412
[20.]
L. Gong, W. Zhang, Y. Zhu, J. Zhu, D. Kong, V. Page, P. Ghadirian, J. Lelorier, P. Hamet, 11 collaborating centers in the Shangai area.
Shangai trial of nifedipine in the elderly (STONE).
J Hypertens, 14 (1996), pp. 1237-1245
[21.]
L. Liu, J.G. Wang, L. Gong, G. Liu, J.A. Staessen.
for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo for older Chinese patients with isolated systolic hypertension.
J Hypertens, 16 (1998), pp. 1823-1829
[22.]
J.A. Staessen, R. Fagard, L. Thijs, H. Celis, G.C. Arabidze, W.H. Birkenhager, et al.
For the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension.
Lancet, 350 (1997), pp. 757-764
[23.]
J. Tuomiletho, D. Rastenyte, W.H. Birkenhäger, et al.
Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension.
N Engl J Med, 340 (1999), pp. 677-684
[24.]
F. Forette, M.L. Seux, J.A. Staessen, L. Thijs, W.H. Birkenhager, M.R. Babarshieke, et al.
Prevention of dementia in randomised double blind placebo controlled Systolic Hypertension in Europe (Syst-Eur) trial.
Lancet, 352 (1998), pp. 1347-1351
[25.]
P.J. Savage, S.L. Pressel, J.D. Curb, E.B. Schron, W.B. Applegate, H.R. Black, et al.
Influence of long-term low dose diuretic based antihypertensive therapy on glucosa, lipid, uric acid and potasium in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group.
Arch Intern Med, 158 (1998), pp. 741-751
[26.]
Blood Pressure Lowering treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood-pressurelowering drugs: results of prospective designed overviews of randomised trials.
Lancet, 356 (2000), pp. 1955-1964
[27.]
B. Pitt, R.P. Byington, C.D. Furberg, D.B. Hunninghake, B.J. Mancini, M.E. Miller.
et al for the PREVENT Investigators. Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events.
Circulation, 102 (2000), pp. 1503-1510
[28.]
S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators.
N Engl J Med, 342 (2000), pp. 145-153
[29.]
S. MacMahon, N. Sharpe, G. Gamble, A. Clague, C. Ni Mhurchu, T. Clark, et al.
PART-2 Collaborative Research Group. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease.
J Am Coll Cardiol, 36 (2000), pp. 438-443
[30.]
L. Cashin-Hemphilla, G. Holmvanga, R. Chan, B. Pitt, R. Dinsmore, R. Lees.
for the QUIET Investigators. Angiotensin converting enzyme inhibition as antiatherosclerotic therapy: no answer yet.
Am J Cardiol, 83 (1999), pp. 43-47
[31.]
K. Teo, J. Burton, C. Buller, S. Plante, D. Catellier, W. Tymchak.
et al for the SCAT Investigators. Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).
Circulation, 102 (2000), pp. 1748-1754
[32.]
L. Hansson, L.H. Lindholm, L. Niskanen, J. Lanke, T. Hedner, A. Niklason, et al.
Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomized trial.
Lancet, 353 (1999), pp. 611-616
[33.]
L. Hansson, L. Lindholm, T. Ekborm, B. Dahlof, J. Lanke, B. Schersten, et al.
Randomised trial of old and new antyhipertensives drugs in elderly patients: cardiovascular mortality and morbidity the Swedich Trial in Old Patients with Hypertension-2 study.
Lancet, 345 (1999), pp. 1751-1756
[34.]
UK Prospective Diabetes Study Group.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.
BMJ, 317 (1998), pp. 703-713
[35.]
L. Hansson, T. Hedner, P. Lund-hohansen, S.E. Kjeldsen, L.H. Lindholm, J.O. Syvertsen, a.l. ety.
for the NORDIL Study Group. Randomised trial of effects of calcium antagonists compared with diuretics an B-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.
Lancet, 356 (2000), pp. 359-365
[36.]
M.J. Brown, C.R. Palmer, A. Castaigne, P.W. de Leeuw, G. Mancia, T. Rosenthal, et al.
Morbidity and mortality in patients randomised to doubleblind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
Lancet, 356 (2000), pp. 366-372
[37.]
A. Simon, J. Gariépy, D. Moyse, J. Levenson.
Differential Effects of Nifedipine and Co-Amilozide on the Progression of Early Carotid Wall Changes.
Circulation, 103 (2001), pp. 2949-2954
[38.]
National Intervention Cooperative Study in Elderly Hypertensives Study Group.
Randomised double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensive.
Hypertension, 34 (1999), pp. 1129-1133
[39.]
A. Zanchetti, E. Agabiti-Rosei, C. Dal Palu, G. Leonetti, B. Magnani, A. Pessina.
The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomised treatment with either verapamil or chlortalidone on intima-media thickness.
J Hypertens, 16 (2000), pp. 1667-1676
[40.]
R. Estacio, B. Jeffers, W. Hiatt, S. Biggerstaff, N. Gifford, R. Schrier.
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.
N Engl J Med, 338 (1998), pp. 645-652
[41.]
B. Dahlöf, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, et al.
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet, 359 (2002), pp. 995-1003
[42.]
B.R. Davis, J.A. Cutler, D.J. Gordon, C.D. Furberg, J.T. Wright, W.C. Cushman, et al.
Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Am J Hypertens, 9 (1996), pp. 342-350
[43.]
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
ALLHAT Collaborative Research Group.
JAMA, 283 (2000), pp. 1967-1975
[44.]
L. Hansson, A. Zanchetti, S.G. Carruthers, B. Dahlof, D. Elmfeldt, J. Menard, et al.
for the HOT Study Group. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
Lancet, 351 (1998), pp. 1755-1762
[45.]
Antiplatelet Trialists' Collaboration.
Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.
BMJ, 308 (1994), pp. 81-106
[46.]
S. Yusuf, R. Peto, J. Lewis, R. Collins, P. Sleight.
Beta blockade during and after myocardial infarction: an overview of the randomized trials.
Prog Cardiovasc Dis, 27 (1985), pp. 335-371
[47.]
A.L. Gould, J.E. Rossouw, N.C. Santanello, J.F. Heyse, C.D. Furberg.
Cholesterol reduction yields clinical benefit. Impact of statin trials.
Circulation, 97 (1998), pp. 946-952
[48.]
J.C. La Rosa, J. He, S. Vupputuri.
Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials.
JAMA, 282 (1999), pp. 2340-2346
[49.]
R. Garg, S. Yusuf.
for The Collaborative Group on ACE Inhibitor Trials. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with he-art failure.
JAMA, 273 (1995), pp. 1450-1456
[50.]
The Heart Outcomes Prevention Evaluation (HOPE) Study investigators.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.
Lancet, 355 (2000), pp. 253-259
[51.]
PROGRESS Collaborative Group.
Randomised trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack.
Lancet, 358 (2001), pp. 1033-1041
[52.]
B.S. Bloom.
Continuation of initial antihypertensive medication after 1 year of therapy.
Clin Ther, 20 (1998), pp. 671-681
[53.]
Guía sobre el diagnóstico y el tratamiento de la hipertensión arterial en España 2002 Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA).
Hipertensión, 19 (2002), pp. S34-S41
[54.]
L. Hansson, H. Lithell, I. Skoog, F. Baro, C.M. Banki, M. Breteler, et al.
Study on Cognition and Prognosis in the Elderly (SCOPE): baseline characteristics.
Blood Pressure, 9 (2000), pp. 146-151
[55.]
C. Bulpitt, A. Fletcher, N. Beckett, J. Coope, B. Gil-Extremera, F. Forette, et al.
The Hypertension in the Very Elderly Trial (HYVET). Protocol for the main trial.
Drugs & Aging, 18 (2001), pp. 151-164
[56.]
E. Malacco, A.E. Gnemmi, A. Romagnoli, A. Coplini.
on Behalf of the SHELL Study Group. Systolic Hypertension in the Elderly: Longterm Lacidipine Treatment. Objetive, protocol and organization.
J Cardiovasc Pharmacol, 23 (1994), pp. S62-S66
[57.]
Management Committee on behalf of the High Blood Pressure Research Council of Australia.
Australian comparative outcome trial of angiotensin-converting enzyme inhibitor and diuretic-based treatment of hypertension in the elderly (ANBP2): objetives and protocol.
Clin Exp Pharmacol Phisiol, 24 (1997), pp. 188-192
[58.]
K.M. Fox, J.R. Henderson, M.E. Bertrand, R. Ferrari, W.J. Remme, M.L. Simons.
The European Trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
Eur Heart J, 19 (1998), pp. J52-J55
[59.]
M.A. Pfeffer, M. Domansky, Y. Rosenberg, J. Verter, N. Geller, P. Albert, et al.
Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design).
Am J Cardiol, 82 (1998), pp. 25H-30H
[60.]
J. Lubsen, P.A. Poole-Wilson, S.J. Pocock, F.J. Van Dalen, J. Baumann, B.A. Kirwan, et al.
Design and current status of ACTION: A coronary disease Trial Investigating Outcome with Nifedipine GITS.
Eur Heart J, 19 (1998), pp. 120-132
[61.]
S.E. Kjeldsen, S. Julius, H. Brunner, L. Hansson, M. Henis, S. Ekman, et al.
Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Longterm Use Evaluation.
Blood Pressure, 10 (2001), pp. 83-91
[62.]
C.J. Pepine, E. Handberg-Thurmond, R.G. Marks, M. Conlon, R. Cooper-DeHoff, P. Volkers, et al.
Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): An internet-based randomized trial in coronary artery disease patients with hypertension.
JACC, 32 (1998), pp. 1228-1237
[63.]
J.r. Wright JT, J.W. Kusek, R.D. Toto, J.Y. Lee, L.Y. Agodoa, K.A. Kirk, et al.
Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study.
Control Clin Trials, 17 (1996), pp. 3S-16S
[64.]
J.B. Kostis, M.A. Weber, M.H. Alderman, H.R. Black, C.I. Johnston, P. Laroche, et al.
OPERA: design and rationale for a novel placebo control trial testing the benefits of blood pressure reduction in patients with stage I isolated systolic hypertension.
Am J Hypertens, 13 (2000), pp. 70A
[65.]
B. Dahlof, P.S. Sever, N.R. Poulter, H. Wedel.
On behalf of the ASCOT steering committee. International Society Hypertension 1998.
J Hypertens, 16 (1998), pp. S2-S12
Copyright © 2002. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
